Business Wire

YARD-FORCE-UK

19.1.2023 06:23:36 CET | Business Wire | Press release

Share
TV Gardener & Chartered Horticulturist, David Domoney Highlights the Best Time to Do Gardening Jobs Using Power Tools

David Domoney highlights the ever-growing garden trend of manicuring. Keeping a neat and tidy garden is important, especially with the rise in popularity of outdoor entertaining. From trimming hedges and edges of lawns to cleaning your patio for a pristine garden, choosing the right tool for the job is crucial. With so much choice in the market, selecting powered garden tools to make the job of garden manicuring both easy, professional and all importantly, fun is a hot topic. In partnering with Yard Force®, David Domoney hopes to encourage people into their gardens and highlight the right time to do specific green preening tasks in the year. Utilising the tools at the right time of the year ensures you get the most out of them as well as making sure your garden is in the best shape.

David said, “By selecting the right tool for the job, it enables you to get the task at hand done most effectively and efficiently, so you have more time to spend enjoying a beautiful garden. In learning when is best to trim hedges, mow the lawn and general garden maintenance, we make time in the garden so much more enjoyable whilst protecting garden wildlife. It opens doors to learning new gardening techniques that will become part of regular gardening routines for a well-cared-for garden.”

Yard Force® is an internationally recognised brand with years of industry experience and knowledge.

David continues, “Giving people access to a better gardening experience is always a good thing; with practical advice on making the most of their garden and the tools necessary to give great results with little effort. The more we can do using professional electric-powered equipment at the right time of year, leaves us more time to enjoy the garden.

I want to make the tasks in the garden both rewarding and fun and using practical power tools that take the hard work out of garden maintenance. The range of cordless products and battery-share technology makes the range hassle-free, convenient, and a more sustainable option for beginners and keen gardeners alike. Within Yard Force’s 40V range, there is the Cordless Lawnmower, Hedge Trimmer, Grass Trimmer which are really innovative products that showcase game-changing technology.”

The partnership between David Domoney and Yard Force continues to encourage budding gardeners and virtuosos to get outside and give their gardens the best care. Through instructive videos, demos, gardening tips and fantastic giveaways, the knowledge and expertise will promote the range and how to get the most from the tools.

Notes to Editors:

David Domoney:

David Domoney is a seasoned gardening television broadcaster and currently presents on ITV’s ‘Love Your Garden’, ‘Love Your Weekend’ and is also the gardening presenter for ITV’s ‘This Morning’. He is a winner of 30 RHS Medals with two Best in Show category trophies and the Prince Edward Award for Horticulture Excellence. David is also known for pioneering campaigns Cultivation Street as well as Illumination Street, brightening up Britain’s streets at Christmas. David also writes a gardening column for Grow Your Own magazine.

www.daviddomoney.com

Yard Force UK:

Yard Force are excited and proud to announce that we have partnered with seasoned gardening television presenter David Domoney to endorse our range of innovative, durable and high-performance garden power tools.

David is best known for presenting ITV’s most popular Gardening Show ‘Love your Garden’ and is also the resident gardening presenter for ITV’s flagship daytime show ‘This Morning’.

David's 40 years’ of experience in horticulture and dynamic enthusiastic character made him the perfect choice to collaborate with to help endorse our innovative and quality lead products.

Introducing a household name to represent our brand instils the confidence we have in our products and their performance. David says:

‘Like anything in the garden, once you know how, it becomes so easy. In learning how to look after our gardens properly, using power tools where needed, we make time in the garden so much more enjoyable and open doors to learning new gardening techniques and having access to a healthy and well-cared-for garden.”

We will be working closely with David throughout the year to produce top gardening tips for you to use around the garden, create some instructive videos designed to encourage you and your family to get back outside and exciting GIVEAWAYS featuring chosen products. To be in with the chance of winning and accessing these great promotions we have created a dedicated promotional code which will enable you to receive discounts and added extras all year round! All you need to do is:

SIGN UP TO RECEIVE THE PROMOTIONAL CODE below:
www.yardforce.eu/david

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005607/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye